Cargando...

Distribution of Gefitinib to the Brain Is Limited by P-glycoprotein (ABCB1) and Breast Cancer Resistance Protein (ABCG2)-Mediated Active Efflux

Gefitinib is an orally active inhibitor of the epidermal growth factor receptor approved for use in patients with locally advanced or metastatic non–small cell lung cancer. It has also been evaluated in several clinical trials for treatment of brain tumors such as high-grade glioma. In this study, w...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Agarwal, Sagar, Sane, Ramola, Gallardo, Jose L., Ohlfest, John R., Elmquist, William F.
Formato: Artigo
Lenguaje:Inglês
Publicado: The American Society for Pharmacology and Experimental Therapeutics 2010
Materias:
Acceso en línea:https://ncbi.nlm.nih.gov/pmc/articles/PMC2912048/
https://ncbi.nlm.nih.gov/pubmed/20421331
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1124/jpet.110.167601
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!